ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALK Positive, Inc. Sponsors Real-World Registry that Confirms the Success of Modern ALK Therapy, and the Contribution of ALK Positive’s Collaborative Clinical Trial Efforts.
The ALK Life Study, a global, patient-led observational registry and longitudinal survey created by ALK Positive, Inc. for patients with ALK-positive (ALK+) non-small cell lung cancer, has published its findings in JCO Global Oncology. The study tracks the natural history of the disease, diagnostic timelines, and real-world treatment patterns over time. Led by patient advocate…
-
New Phase 1 Trial Will Explore AQUA07 in ALK-positive NSCLC
Clinical Trial ID NCT07617337
-
Clinical Trials Update: ALK Research Makes a Big Splash @ The ASCO Conference
New Hope from ASCO 2026 Each year, the American Society of Clinical Oncology (ASCO) hosts cancer researchers from around the world to share their latest discoveries. At this year’s meeting in Chicago, researchers presented many new findings on ALK-positive lung cancer. The overall message was encouraging: targeted therapies continue to improve outcomes, treatment options are expanding, and researchers are finding…
-
Patient Spotlight: Laura Reed
We interviewed Laura Reed – a former US Navy Officer, ALK patient, legacy donor and fundraiser – about her background, navigating her diagnosis, and her involvement with ALK Positive Inc.
-
Strawberry Goat Cheese Crostini
In the summer I love to entertain outdoors. I especially love recipes that require very little cooking or effort. These delicious crostini are bursting with seasonal sweet strawberries, and they come together in about 10 minutes. You might decide to throw a party just to try them! -Juli, Your ALKie Chef
-
Advancing Research Together: Honored to Be Named CTI Cares’ Q3 Charity of the Quarter
Progress against ALK-positive cancer has always been driven by collaboration. Every breakthrough, every clinical trial, and every new treatment is made possible because patients, researchers, clinicians, and organizations come together with a shared purpose: improving the lives of people affected by cancer. That is why we are incredibly honored to be selected as CTI Clinical…
-
Ivonescimab: A phase 2 Clinical Trial NCT07405190 by Akeso, Inc.
Clinical Trial ID NCT07405190
-
Meet Michael Hu: Medical Astronaut
Diagnosed at 43 with two kids at home, Michael Hu has navigated multiple progressions, treatment switches, and the emotional weight of “hurry up and wait” — all while staying at the frontier of his own care.
-
MEET YOUR STAFF: Introducing our first Director of Philanthropy, Roberta Plantak
Roberta joined the ALK Positive, Inc. team in March 2026 as our first Director of Philanthropy and has already been making a big difference. We wanted our readers to get to know her more both in her professional capacity, and “behind the scenes”.
-
Patient Perspective: Hope for ALK+ NSCLC Patients
Jeff Sturm reflects on the emotional reality of living with ALK-positive cancer and the role gratitude, kindness, and community can play in helping patients and families hold onto hope.
-
International Patient Spotlight: Vivian McIntyre
Vivian McIntyre shares her journey from Stage IV diagnosis to becoming involved with ALK Positive Canada and finding connection within the global ALK-positive community.
-
Patient Spotlight: Rick Mallick
We interviewed 18-year ALK survivor Rick Mallick about his long journey with ALK+ lung cancer, the wisdom he has gained along the way, what keeps him grounded, and so much more.